Erythropoietin and Its Angiogenic Activity

Erythropoietin (EPO) is the main hematopoietic hormone acting on progenitor red blood cells via stimulation of cell growth, differentiation, and anti-apoptosis. However, its receptor (EPOR) is also expressed in various non-hematopoietic tissues, including endothelium. EPO is a pleiotropic growth fac...

Descripción completa

Detalles Bibliográficos
Autores principales: Kimáková, Patrícia, Solár, Peter, Solárová, Zuzana, Komel, Radovan, Debeljak, Nataša
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536009/
https://www.ncbi.nlm.nih.gov/pubmed/28703764
http://dx.doi.org/10.3390/ijms18071519
_version_ 1783253945968230400
author Kimáková, Patrícia
Solár, Peter
Solárová, Zuzana
Komel, Radovan
Debeljak, Nataša
author_facet Kimáková, Patrícia
Solár, Peter
Solárová, Zuzana
Komel, Radovan
Debeljak, Nataša
author_sort Kimáková, Patrícia
collection PubMed
description Erythropoietin (EPO) is the main hematopoietic hormone acting on progenitor red blood cells via stimulation of cell growth, differentiation, and anti-apoptosis. However, its receptor (EPOR) is also expressed in various non-hematopoietic tissues, including endothelium. EPO is a pleiotropic growth factor that exhibits growth stimulation and cell/tissue protection on numerous cells and tissues. In this article we review the angiogenesis potential of EPO on endothelial cells in heart, brain, and leg ischemia, as well as its role in retinopathy protection and tumor promotion. Furthermore, the effect of EPO on bone marrow and adipose tissue is also discussed.
format Online
Article
Text
id pubmed-5536009
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-55360092017-08-04 Erythropoietin and Its Angiogenic Activity Kimáková, Patrícia Solár, Peter Solárová, Zuzana Komel, Radovan Debeljak, Nataša Int J Mol Sci Review Erythropoietin (EPO) is the main hematopoietic hormone acting on progenitor red blood cells via stimulation of cell growth, differentiation, and anti-apoptosis. However, its receptor (EPOR) is also expressed in various non-hematopoietic tissues, including endothelium. EPO is a pleiotropic growth factor that exhibits growth stimulation and cell/tissue protection on numerous cells and tissues. In this article we review the angiogenesis potential of EPO on endothelial cells in heart, brain, and leg ischemia, as well as its role in retinopathy protection and tumor promotion. Furthermore, the effect of EPO on bone marrow and adipose tissue is also discussed. MDPI 2017-07-13 /pmc/articles/PMC5536009/ /pubmed/28703764 http://dx.doi.org/10.3390/ijms18071519 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Kimáková, Patrícia
Solár, Peter
Solárová, Zuzana
Komel, Radovan
Debeljak, Nataša
Erythropoietin and Its Angiogenic Activity
title Erythropoietin and Its Angiogenic Activity
title_full Erythropoietin and Its Angiogenic Activity
title_fullStr Erythropoietin and Its Angiogenic Activity
title_full_unstemmed Erythropoietin and Its Angiogenic Activity
title_short Erythropoietin and Its Angiogenic Activity
title_sort erythropoietin and its angiogenic activity
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536009/
https://www.ncbi.nlm.nih.gov/pubmed/28703764
http://dx.doi.org/10.3390/ijms18071519
work_keys_str_mv AT kimakovapatricia erythropoietinanditsangiogenicactivity
AT solarpeter erythropoietinanditsangiogenicactivity
AT solarovazuzana erythropoietinanditsangiogenicactivity
AT komelradovan erythropoietinanditsangiogenicactivity
AT debeljaknatasa erythropoietinanditsangiogenicactivity

Ejemplares similares